Neutralizing antibodies are produced after SARS-CoV-2 infection

A research group from Osaka University led by Professor Hisashi Arase and consisting of researchers from the Research Institute for Microbial Diseases, the Institute for Protein Research, the Immunology Frontier Research Center, the Center for Infectious Diseases, and the Graduate School of Medicine has discovered for the first time that both neutralizing antibodies that protect against infection as well as infection-enhancing antibodies that increase infectivity are produced after infection with SARS-CoV-2 by analyzing antibodies derived from COVID-19 patients.

Antibodies against the receptor binding site (RBD) of the SARS-CoV-2 spike protein play an important function as neutralizing antibodies that suppress SARS-CoV-2 infection by inhibiting its binding to the human receptor, ACE2. On the other hand, the function of antibodies against other sites of the spike protein was unknown.

We found that when infection-enhancing antibodies bind to a specific site on the spike protein of SARS-CoV-2, the antibodies directly cause a conformational change in the spike protein, resulting in the increased infectivity of SARS-CoV-2."

Hisashi Arase, Professor, Osaka University

Neutralizing antibodies recognize the RBD, whereas infection-enhancing antibodies recognize specific sites of the N-terminal domain (NTD)," explains Professor Hisashi Arase. "Furthermore, the production of infection-enhancing antibodies attenuated the ability of neutralizing antibodies to prevent infection."

Higher production of infection-enhancing antibodies was found in patients with severe COVID-19. It was also found that non-infected individuals may have small amounts of infection-enhancing antibodies.

Although the production of infection-enhancing antibodies may be involved in the development of severe disease, further analysis is required to ascertain whether they are actually involved in the exacerbation of infection in the body.

By analyzing the antibody titer of infection-enhancing antibodies, it may be possible to check for people who are prone to severe disease. The results of this research are also important for the development of vaccines that do not induce the production of infection-enhancing antibodies.

"It is important to analyze not only neutralizing antibodies but also infection-enhancing antibodies. In the future, it may be necessary to develop vaccines that do not induce the production of infection-enhancing antibodies, because infection-enhancing antibodies may be more effective against mutant strains in which neutralizing antibodies are not sufficiently effective," says Professor Hisashi Arase.

Source:
Journal reference:

Liu, Y., et al. (2021) An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies. Cell. doi.org/10.1016/j.cell.2021.05.032.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Osaka University. (2022, December 14). Neutralizing antibodies are produced after SARS-CoV-2 infection. AZoLifeSciences. Retrieved on May 30, 2024 from https://www.azolifesciences.com/news/20210526/SARS-CoV-2-not-only-produces-neutralizing-antibodies-but-also-infection-enhancing-antibodies.aspx.

  • MLA

    Osaka University. "Neutralizing antibodies are produced after SARS-CoV-2 infection". AZoLifeSciences. 30 May 2024. <https://www.azolifesciences.com/news/20210526/SARS-CoV-2-not-only-produces-neutralizing-antibodies-but-also-infection-enhancing-antibodies.aspx>.

  • Chicago

    Osaka University. "Neutralizing antibodies are produced after SARS-CoV-2 infection". AZoLifeSciences. https://www.azolifesciences.com/news/20210526/SARS-CoV-2-not-only-produces-neutralizing-antibodies-but-also-infection-enhancing-antibodies.aspx. (accessed May 30, 2024).

  • Harvard

    Osaka University. 2022. Neutralizing antibodies are produced after SARS-CoV-2 infection. AZoLifeSciences, viewed 30 May 2024, https://www.azolifesciences.com/news/20210526/SARS-CoV-2-not-only-produces-neutralizing-antibodies-but-also-infection-enhancing-antibodies.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
High tumor-infiltrating lymphocytes could indicate a better chance of survival in esophageal cancer